Cargando…
Permanent (125)I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence
PURPOSE: To evaluate predictive factors for PSA bounce after (125)I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. MATERIALS AND METHODS: Men treated with exclusive permanent (125)I seed brachytherapy from November 1999,...
Autores principales: | Mazeron, Renaud, Bajard, Agathe, Montbarbon, Xavier, Gassa, Frédéric, Malet, Claude, Rocher, François, Clippe, Sébastien, Bringeon, Gabriel, Desmettre, Olivier, Pommier, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342157/ https://www.ncbi.nlm.nih.gov/pubmed/22449081 http://dx.doi.org/10.1186/1748-717X-7-46 |
Ejemplares similares
-
Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival
por: Robin, Sophie, et al.
Publicado: (2021) -
Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018) -
Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy
por: Yamamoto, Yoichiro, et al.
Publicado: (2016) -
Clinical features of prostate-specific antigen bounce after (125)I brachytherapy for prostate cancer
por: Kubo, Katsumaro, et al.
Publicado: (2018) -
Prostate-Specific Antigen Bounce after (125)I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer
por: Kim, Tae Hyung, et al.
Publicado: (2022)